The Nevada Cancer Research Foundation (NCRF) was established in 1983 to conduct cancer research under the National Cancer Institute's (NCI), Community Clinical Oncology Program (CCOP) grant. The NCRF main office is located in central Las Vegas with satellite offices in Reno and Carson City, Nevada. It is Our Mission to provide high quality, state-of-the-art, cancer treatment research and cancer control and prevention research in Nevada through the participation of the local physicians and health care providers at their facilities.'It is also our intent to provide high quality, timely data to the NCI in a research environment that sets the highest standards for the safety and welfare of our participants. The long term NCRF CCOP grant objectives have been: 1) to accrue a minimum of 50 participants annually to CCOP approved cancer treatment clinical trials in Nevada;2) to accrue a minimum of 50 participants to CCOP approved cancer control and prevention studies in Nevada;3) to provide to the Research Bases timely data of high quality. 4) to promote quality and state-of-the-art treatment in the community through participation in clinical trials by: (a) involving CCOP physicians and staff in scientific and educational activities of the Research Bases;(b) expanding the knowledge, awareness, and involvement of the primary healthcare providers and specialists in the Research Base activities for the development and use of cancer prevention and control research;5) to support other professional education programs and cancer prevention and control outreach services to under-served rural areas;6) to identify women and minority groups that may be underserved and to involve them in clinical trials;and 7) to continue to work with the NCI to develop a community cancer network in order to facilitate the growth, development, and implementation of important new cancer initiatives. To accomplish these goals, the NCRF CCOP makes the program available to all interested professionals from varied medical specialties for state-wide participation thereby providing access for participation to the citizens of Nevada. Essential to our mission is the service we provide to our participants. We encourage involvement by closely following all aspects of their health care, protecting their welfare, and by providing the latest information and resources available. We are here specifically to provide a service to Nevada residents and generally to provide a service to all who are afflicted with this disease.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-3 (J1))
Program Officer
Whitman, Cynthia B
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Southern Nevada Cancer Research Fdn
Las Vegas
United States
Zip Code
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Yu, Evan Y; Li, Hongli; Higano, Celestia S et al. (2015) SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 33:1601-8
Lilenbaum, Rogerio; Samuels, Michael; Wang, Xiaofei et al. (2015) A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). J Thorac Oncol 10:143-7
Smith, Matthew R; Halabi, Susan; Ryan, Charles J et al. (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143-50
Kolitz, Jonathan E; George, Stephen L; Benson Jr, Don M et al. (2014) Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer 120:1010-7

Showing the most recent 10 out of 59 publications